• Mitochondrial mt12361A>...

Treffer: Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes.

Title:
Mitochondrial mt12361A>G increased risk of metabolic dysfunction-associated steatotic liver disease among non-diabetes.
Authors:
Lu MY; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan.; School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung 80708, Taiwan., Wei YJ; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Wang CW; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Liang PC; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Yeh ML; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Tsai YS; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Tsai PC; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Ko YM; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Lin CC; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Chen KY; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Lin YH; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Jang TY; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Hsieh MY; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Lin ZY; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Huang CF; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Huang JF; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Dai CY; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Chuang WL; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan., Yu ML; Hepatitis Center and Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung 80708, Taiwan.; School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung 80708, Taiwan. fish6069@gmail.com.
Source:
World journal of gastroenterology [World J Gastroenterol] 2025 Mar 14; Vol. 31 (10), pp. 103716.
Publication Type:
Journal Article
Language:
English
Journal Info:
Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 100883448 Publication Model: Print Cited Medium: Internet ISSN: 2219-2840 (Electronic) Linking ISSN: 10079327 NLM ISO Abbreviation: World J Gastroenterol Subsets: MEDLINE
Imprint Name(s):
Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group
Original Publication: Beijing : WJG Press, c1998-
MeSH Terms:
Boosting Machine Learning Algorithms* , DNA, Mitochondrial*/genetics , Non-alcoholic Fatty Liver Disease*/complications , Non-alcoholic Fatty Liver Disease*/diagnosis , Non-alcoholic Fatty Liver Disease*/genetics, Adult ; Humans ; Male ; Middle Aged ; Cohort Studies ; Diabetes Complications/diagnosis ; Diabetes Complications/genetics ; Logistic Models ; Polymorphism, Single Nucleotide ; Random Forest ; Case-Control Studies
References:
Methods Mol Biol. 2006;336:135-43. (PMID: 16916259)
J Hepatol. 2024 Feb;80(2):e72-e74. (PMID: 37678721)
Clin Mol Hepatol. 2024 Jan;30(1):64-79. (PMID: 38195113)
Nat Metab. 2021 Dec;3(12):1596-1607. (PMID: 34931080)
World J Gastroenterol. 2014 Aug 21;20(31):10851-63. (PMID: 25152587)
Life Sci. 2023 Sep 15;329:121943. (PMID: 37454757)
Nat Metab. 2024 Jun;6(6):1024-1035. (PMID: 38689023)
Science. 1998 Aug 28;281(5381):1309-12. (PMID: 9721092)
Eur J Intern Med. 2024 Apr;122:11-19. (PMID: 38246813)
J Hepatol. 2024 Sep;81(3):492-542. (PMID: 38851997)
Mitochondrion. 2010 Apr;10(3):294-9. (PMID: 20067846)
Cell Metab. 2015 May 5;21(5):739-46. (PMID: 25955209)
Liver Int. 2024 Jan;44(1):61-71. (PMID: 37718933)
Clin Gastroenterol Hepatol. 2022 Dec;20(12):2809-2817.e28. (PMID: 34890795)
BMC Med Genet. 2016 Sep 05;17(1):63. (PMID: 27596100)
J Clin Invest. 1996 Jul 15;98(2):345-51. (PMID: 8755643)
J Gastroenterol Hepatol. 2024 Sep;39(9):1939-1949. (PMID: 38725327)
J Intern Med. 2021 Jan;289(1):84-96. (PMID: 32634278)
J Hepatol. 2023 Feb;78(2):415-429. (PMID: 36209983)
Cell. 2021 May 13;184(10):2537-2564. (PMID: 33989548)
Front Endocrinol (Lausanne). 2022 Aug 25;13:968268. (PMID: 36093112)
Nat Rev Cancer. 2021 Jul;21(7):431-445. (PMID: 34045735)
Am J Med Genet. 1998 Jun 5;77(5):395-400. (PMID: 9632169)
Front Public Health. 2022 Apr 04;10:846118. (PMID: 35444985)
J Hepatol. 2020 Jun;72(6):1196-1209. (PMID: 32145256)
Hepatology. 2013 Oct;58(4):1497-507. (PMID: 23299992)
Liver Int. 2022 Nov;42(11):2377-2389. (PMID: 35986897)
Hepatology. 2010 Nov;52(5):1836-46. (PMID: 21038418)
Gastroenterology. 2015 Aug;149(2):389-97.e10. (PMID: 25935633)
Kaohsiung J Med Sci. 2024 Nov;40(11):962-971. (PMID: 39440678)
Biochem Res Int. 2012;2012:387626. (PMID: 22745910)
Clin Mol Hepatol. 2023 Oct;29(4):969-972. (PMID: 37718552)
Antioxidants (Basel). 2024 Jul 26;13(8):. (PMID: 39199152)
Surgery. 2023 Sep;174(3):723-726. (PMID: 37419761)
Nat Med. 2018 Sep;24(9):1304-1305. (PMID: 30177823)
Nat Genet. 2023 Oct;55(10):1640-1650. (PMID: 37709864)
Cells. 2019 Jul 05;8(7):. (PMID: 31284394)
Hepatology. 2023 Jul 1;78(1):258-271. (PMID: 36994719)
Ann Hepatol. 2024 Dec 17;30(1):101774. (PMID: 39701281)
Aging (Albany NY). 2020 Mar 26;12(7):6467-6485. (PMID: 32213662)
Clin Gastroenterol Hepatol. 2012 Dec;10(12):1342-1359.e2. (PMID: 23041539)
Endocrinol Diabetes Metab. 2020 Oct 06;4(1):e00187. (PMID: 33532620)
Biology (Basel). 2023 Apr 14;12(4):. (PMID: 37106795)
Gut. 2024 Mar 7;73(4):691-702. (PMID: 38228377)
Hormones (Athens). 2019 Dec;18(4):463-475. (PMID: 31656024)
Anal Chim Acta. 2020 Sep 22;1131:146-155. (PMID: 32928475)
Biomolecules. 2021 Mar 22;11(3):. (PMID: 33810079)
Cell Metab. 2020 Dec 1;32(6):1012-1027.e7. (PMID: 33152322)
J Hepatol. 2024 Feb;80(2):e54-e56. (PMID: 37541393)
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241250324. (PMID: 38775067)
Gut. 2013 Sep;62(9):1356-63. (PMID: 22879518)
Mitochondrion. 2006 Feb;6(1):1-28. (PMID: 16406828)
Sci Rep. 2023 Mar 3;13(1):3638. (PMID: 36869105)
Transl Res. 2012 Jan;159(1):58-9. (PMID: 22153811)
J Hepatol. 2023 Sep;79(3):842-852. (PMID: 37169151)
Diabetes Care. 2022 Apr 1;45(4):928-937. (PMID: 35113139)
Clin Mol Hepatol. 2023 Feb;29(Suppl):S171-S183. (PMID: 36503204)
Autophagy. 2015 Nov 2;11(11):1956-1977. (PMID: 26389781)
Hepatology. 2023 Apr 1;77(4):1348-1365. (PMID: 35971873)
Hepatology. 2023 May 1;77(5):1797-1835. (PMID: 36727674)
Nat Med. 2018 Jul;24(7):908-922. (PMID: 29967350)
Int J Mol Sci. 2021 Apr 27;22(9):. (PMID: 33925624)
Antioxidants (Basel). 2021 Jan 26;10(2):. (PMID: 33530432)
J Pathol. 2016 Dec;240(4):437-449. (PMID: 27577682)
Genes Dis. 2023 Sep 17;11(3):101115. (PMID: 38299199)
Contributed Indexing:
Keywords: Algorithm; Artificial intelligence; Machine learning; Metabolic dysfunction-associated steatotic liver disease; Mitochondrial DNA
Substance Nomenclature:
0 (DNA, Mitochondrial)
Entry Date(s):
Date Created: 20250317 Date Completed: 20250318 Latest Revision: 20250318
Update Code:
20250319
PubMed Central ID:
PMC11886537
DOI:
10.3748/wjg.v31.i10.103716
PMID:
40093674
Database:
MEDLINE

Weitere Informationen

Background: Insulin resistance, lipotoxicity, and mitochondrial dysfunction contribute to the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). Mitochondrial dysfunction impairs oxidative phosphorylation and increases reactive oxygen species production, leading to steatohepatitis and hepatic fibrosis. Artificial intelligence (AI) is a potent tool for disease diagnosis and risk stratification.
Aim: To investigate mitochondrial DNA polymorphisms in susceptibility to MASLD and establish an AI model for MASLD screening.
Methods: Multiplex polymerase chain reaction was performed to comprehensively genotype 82 mitochondrial DNA variants in the screening dataset ( n = 264). The significant mitochondrial single nucleotide polymorphism was validated in an independent cohort ( n = 1046) using the Taqman <sup>®</sup> allelic discrimination assay. Random forest, eXtreme gradient boosting, Naive Bayes, and logistic regression algorithms were employed to construct an AI model for MASLD.
Results: In the screening dataset, only mt12361A>G was significantly associated with MASLD. mt12361A>G showed borderline significance in MASLD patients with 2-3 cardiometabolic traits compared with controls in the validation dataset ( P = 0.055). Multivariate regression analysis confirmed that mt12361A>G was an independent risk factor of MASLD [odds ratio (OR) = 2.54, 95% confidence interval (CI): 1.19-5.43, P = 0.016]. The genetic effect of mt12361A>G was significant in the non-diabetic group but not in the diabetic group. mt12361G carriers had a 2.8-fold higher risk than A carriers in the non-diabetic group (OR = 2.80, 95%CI: 1.22-6.41, P = 0.015). By integrating clinical features and mt12361A>G, random forest outperformed other algorithms in detecting MASLD [training area under the receiver operating characteristic curve (AUROC) = 1.000, validation AUROC = 0.876].
Conclusion: The mt12361A>G variant increased the severity of MASLD in non-diabetic patients. AI supports the screening and management of MASLD in primary care settings.
(©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.)

Conflict-of-interest statement: The authors declare that they have no conflict of interest.